Asymchem Laboratories (Tianjin) Co., Ltd.
002821
株式のランク
#2511
Asymchem Laboratories (Tianjin) Co., Ltd. functions as a contract development... Asymchem Laboratories (Tianjin) Co., Ltd. functions as a contract development and manufacturing organization (CDMO), offering its expertise to pharmaceutical and biotechnology companies both globally and within Mainland China. Their services encompass drug research, development, and production, supporting projects across the entire drug lifecycle, from early clinical phases to commercial scale. This includes R&D and cGMP-compliant manufacturing of advanced intermediates, active pharmaceutical ingredients (APIs), and finished drug formulations, in addition to providing clinical research support. Furthermore, Asymchem engages in pharmaceutical analysis and testing, the distribution (wholesale, retail, and direct sale) of medicines, and initiatives focused on advancing pharmaceutical science and technology. The company, established in 1999, maintains its headquarters in Tianjin, China.
株価
$20.91
時価総額
$7.57B
変化（1日）
-8.26%
変化（1年）
41.25%
国
CN
取引 Asymchem Laboratories (Tianjin) Co., Ltd. (002821)
カテゴリー
Healthcare
Asymchem Laboratories (Tianjin) Co., Ltd.（002821）の収益
Jun 2026 時点の収益 TTM: $1.06B
Asymchem Laboratories (Tianjin) Co., Ltd. の最新の財務報告によると、現在の収益 (TTM) は $1.06B です。2024 年には $795.26M の収益があり、これは 2023 年の $1.11B と比較して 減少 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Asymchem Laboratories (Tianjin) Co., Ltd. の収益履歴（2011 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $1.06B | 11.34% |
| 2025 | $953.37M | 19.88% |
| 2024 | $795.26M | -28.06% |
| 2023 | $1.11B | -25.46% |
| 2022 | $1.48B | 103.50% |
| 2021 | $728.79M | 51.78% |
| 2020 | $480.16M | 35.91% |
| 2019 | $353.28M | 32.44% |
| 2018 | $266.75M | 21.96% |
| 2017 | $218.72M | 37.65% |
| 2016 | $158.90M | 24.23% |
| 2015 | $127.91M | 10.62% |
| 2014 | $115.63M | 29.23% |
| 2013 | $89.48M | 31.47% |
| 2012 | $68.06M | 5.76% |
| 2011 | $64.35M | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $12.62B | 1,089.29% |
US
|
|
| $2.23B | 109.89% |
US
|
|
| $15.74B | 1,383.22% |
AU
|
|
| $9.57B | 801.80% |
BE
|
|
| $6.02B | 467.25% |
NL
|
